An update from Novacyt ( (FR:ALNOV) ) is now available.
Novacyt S.A. has announced its monthly update regarding its liquidity agreement with Invest Securities SA, detailing the purchase and sale of ordinary shares in March 2025. The company has 87,900 ordinary shares held in treasury, with a total of 70,626,248 ordinary shares available, which stakeholders can use to assess their shareholding interests. This update reflects Novacyt’s ongoing efforts to manage its share liquidity and maintain transparency with its shareholders.
More about Novacyt
Novacyt is an international molecular diagnostics company specializing in genomic medicine. It develops, manufactures, and commercializes a range of molecular assays and instrumentation, offering end-to-end solutions across human health, animal health, and environmental sectors. The company operates through three business segments: Clinical, Instrumentation, and Research Use Only, and is headquartered in Le Vésinet, France, with a presence in over 65 countries.
YTD Price Performance: -15.81%
Average Trading Volume: 200
Technical Sentiment Signal: Buy
Current Market Cap: $38.75M
Learn more about ALNOV stock on TipRanks’ Stock Analysis page.